Therapeia, Telix deal
Therapeia granted Telix rights to ACD-101 to treat glioblastoma and an exclusive option to acquire Therapeia, which Telix plans to exercise in 2Q17. Telix said it expects the synthetic amino acid that...
BCIQ Company Profiles
BCIQ Target Profiles